[Ezetimibe-rosuvastatin fixed-dose combination (Myrosor®)]

Area of Science:

• Cardiology
• Pharmacology
• Metabolic Diseases

Background:

• International guidelines increasingly emphasize stringent low-density lipoprotein (LDL) cholesterol targets, particularly for individuals with very high or high cardiovascular risk.
• Achieving these targets often necessitates potent lipid-lowering therapies.
• When maximal statin doses are insufficient or not tolerated, combination therapy is recommended.

Purpose of the Study:

• To describe the characteristics of a fixed-dose combination of rosuvastatin and ezetimibe.
• To highlight the efficacy and tolerability of this combination therapy for LDL cholesterol management.

Main Methods:

• The article reviews the pharmacological properties of rosuvastatin, a potent statin, and ezetimibe, a cholesterol absorption inhibitor.
• It discusses the rationale for combining these agents.
• The focus is on a specific fixed-dose combination product available in Belgium.

Main Results:

• Combining rosuvastatin and ezetimibe allows for reduced statin dosage while maintaining high efficacy in lowering LDL cholesterol.
• This combination demonstrates a favorable tolerance profile.
• The fixed-dose formulation simplifies treatment regimens.

Conclusions:

• The fixed-dose combination of rosuvastatin and ezetimibe provides an effective and well-tolerated therapeutic option for patients requiring intensive LDL cholesterol reduction.
• This approach supports adherence to strict lipid targets in high-risk cardiovascular populations.